Cancel
Jason T. Gammack
Chief Executive Officer
@
Ansa Biotechnologies
See Linkedin
About Jason T. Gammack
Jason T. Gammack serves as the Chief Executive Officer, leading the company as it transitions from its early access program to a full commercial launch of its rapid enzymatic synthesis technology for complex clonal genes and gene fragments.
Known information
Jason T. Gammack holds the position of Chief Executive Officer at a biotechnology firm that specializes in rapid enzymatic synthesis for complex clonal genes and gene fragments. He joined the company during a pivotal phase as it concluded its early access program and moved towards a full commercial launch. Under his leadership, the company aims to expand its innovative technology into broader markets. The founding CEO, Dan Lin-Arlow, PhD, continues to contribute to the company’s scientific advancements in his new role as Chief Scientific Officer.
About Ansa Biotechnologies
Ansa Biotechnologies, based in Emeryville, CA, specializes in enzyme-based DNA synthesis, focusing on sequences that are challenging to produce with existing methods. The company, part of the Y Combinator W20 batch, has raised $68 million in Series A financing to expand its innovative DNA synthesis technology.
Report inaccurate information
